Original Article
Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men
N Engl J Med 1996; 335:304-310August 1, 1996
- Abstract
Background
The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white populations. We determined the distribution of PSA and age-specific reference ranges in black men both with and without prostate cancer.
Methods
From January 1991 through May 1995, we measured serum PSA in 3475 men with no clinical evidence of prostate cancer (1802 white and 1673 black) and 1783 men with prostate cancer (1372 white and 411 black). We studied the data as a function of age and race to determine the usefulness of measuring PSA in diagnosing prostate cancer.
Results
Serum PSA concentrations in black men (geometric mean in controls, 1.48 ng per milliliter; in patients, 7.46) were significantly higher than those in white men (geometric mean in controls, 1.33 ng per milliliter; in patients, 6.28). The values in the controls correlated directly with age. The area under the receiver-operating-characteristic curve was 0.91 for blacks and 0.94 for whites. If traditional age-specific reference ranges were used in screening black men, with the test specificity kept at 95 percent, 41 percent of cases of prostate cancer would be missed. For the test to have 95 percent sensitivity among black men, the following normal reference ranges should be used: for men in their 40s, 0 to 2.0 ng of PSA per milliliter (test specificity, 93 percent); for men in their 50s, 0 to 4.0 ng per milliliter (specificity, 88 percent); for men in their 60s, 0 to 4.5 ng per milliliter (specificity, 81 percent); and for men in their 70s, 0 to 5.5 ng per milliliter (specificity, 78 percent).
Conclusions
Serum PSA concentrations can be used to discriminate between men with prostate cancer and those without it among both blacks and whites. Over 40 percent of cases of prostate cancer in black men would not be detected by tests using traditional age-specific reference ranges, which maintain specificity at 95 percent. In this high-risk population, the alternative approach — maintaining sensitivity at 95 percent — may be used with acceptable decrements in specificity.
Media in This Article
Figure 1
Serum Concentrations of Prostate-Specific Antigen as a Function of Age and Race in Men with No Clinical Evidence of Prostate Cancer.Figure 2
Receiver-Operating-Characteristic Curves of Sensitivity Plotted against 100 minus Specificity for Men 40 to 79 Years of Age.Article Activity
- Article
With 317,000 new cases and 41,000 deaths predicted for 1996, prostate cancer is now the most common cancer and the second leading cause of death from cancer among men in the United States.1 In blacks the statistics are even more sobering, with a higher incidence of disease, a higher likelihood of diagnosis at a more advanced stage of disease, and a lower rate of survival after adjustment for disease stage than among whites.2 The American Cancer Society, the American Urological Association, and the American College of Radiology have made the controversial recommendation that all men over the age of 50 have an annual blood test for prostate-specific antigen (PSA) and a digital rectal examination to screen for prostate cancer. In black men and men with a family history of prostate cancer, it is recommended that testing begin at the age of 40.3,4 Little is known, however, about the use of PSA tests in the screening of black men for prostate cancer.
PSA is a serine protease produced by the epithelial cells of normal, hyperplastic, and cancerous prostatic tissue.5 Because the enzyme is not specific for prostate cancer, the PSA test has a high false positive rate when used as a screening tool.6 Only 26 percent of men with serum PSA levels between 4.1 and 9.9 ng per milliliter have prostate cancer on biopsy.7
In men without prostate cancer, PSA levels increase with age, mainly because of increases in prostate volume due to benign prostatic hyperplasia. This fact led Oesterling et al. to develop age-specific reference ranges for white men from Olmsted County, Minnesota.8 Other groups have reported normal reference ranges similar to theirs, all based on predominantly white populations of men without prostate cancer, and all designed so that the test would have 95 percent specificity.9-11 Using these ranges can reduce the number of prostate biopsies by 22 percent in men over the age of 70, while potentially increasing the sensitivity of the PSA test in younger men, who are most likely to benefit from treatment.12
Race may also be an important factor in setting a reference range. A recent study found that a population of healthy Japanese men had lower PSA values than a group of white men of similar age.13 We found that blacks with newly diagnosed prostate cancer have higher PSA levels than whites, even after adjustment for the stage, volume, and grade of the tumor and the patient's age.14 For the PSA test to have a similar sensitivity in blacks the normal reference range might be higher than for whites.
In this study, we sought to determine the distribution of serum PSA levels in a large population of blacks and whites both with and without prostate cancer. All the men studied were in the U.S. military system, where there is equal access to health care. All the PSA tests were performed in the same laboratory by the same method. We evaluated the sensitivity and specificity of various reference ranges: the range currently used (0 to 4.0 ng per milliliter); age-specific ranges based on the specificity of the test in whites8; a similar set of ranges based on data from blacks; and a set of age-specific ranges based on data from blacks with prostate cancer in which sensitivity was kept at 95 percent to maximize the detection of cancer.
Methods
Controls
From January 1991 through May 1995, 14,826 men 40 to 79 years of age had a total of 53,789 serum PSA tests performed at Walter Reed Army Medical Center as part of their general health examinations. All the PSA determinations were performed in a central laboratory with the same assay (IMx, Abbott; normal range, 0 to 4.0 ng of PSA per milliliter). The men included 2129 blacks, 312 Asians, 84 men of Hispanic origin, 12,193 whites, and 108 men of unknown race or ethnic group. Data on the men's PSA values, ages, and race or ethnic group were maintained in a central computer, and all the analyses were based on the results of the first test in each man. Patients with prostatitis were excluded, but those with prostatism were not.
A computer-generated random sample of 2100 white men was combined with the entire group of blacks to form the study sample of 4229 men. This cohort was cross-referenced with the data bases of the hospital pathology department and tumor registry, and 465 men with known prostate cancer were excluded from the study. Among the remaining 3764 men, 576 who had abnormal digital rectal examinations (61 men; 37 whites and 24 blacks), PSA values higher than 4.0 ng per milliliter (538 men; 259 whites and 279 blacks), or both but no known prostate cancer were studied. In this subgroup a total of 684 prostate biopsies were performed; in 127 of these patients (48 whites and 79 blacks) the biopsy revealed prostate cancer. There were 162 additional men who were not evaluated further and were excluded from the analysis. The 287 remaining men with PSA values above 4.0 ng per milliliter, an abnormal digital rectal examination, or both were assumed to be free of prostate cancer because transrectal ultrasonography of the prostate, prostate biopsy, or both were negative for cancer. The final study cohort included 3475 men (1802 whites and 1673 blacks) who had no evidence of prostate cancer. Of these men, 8 blacks (0.5 percent) and 12 whites (0.7 percent) were receiving finasteride at the time of their PSA determinations.
Patients
From January 1991 through August 1995, at the same medical center, a total of 1783 men, 411 black and 1372 white, had PSA tests performed during the six months before a subsequent diagnosis of prostate cancer by biopsy. The reason for the prostate biopsy was known in 79 percent of the patients (345 blacks and 1057 whites). In 7 percent of blacks and 15 percent of whites, the only abnormality was on the digital rectal examination, whereas in 38 percent and 40 percent, respectively, the only abnormality was an elevated PSA level (more than 4.0 ng per milliliter); 55 percent and 45 percent, respectively, had both abnormal digital examinations and elevated PSA levels. Less than 0.5 percent of each racial group had symptoms of metastatic prostate cancer as the only reason for biopsy. Twelve blacks (2.9 percent) and 33 whites (2.4 percent) were receiving finasteride at the time of their PSA determinations.
Statistical Analysis
Because of the log-normal distribution of the PSA concentrations, they were log-transformed in the analyses. The observed 5th, 25th, 50th (median), 75th, and 95th percentiles were calculated on the basis of the empirical distribution of the data in each 10-year age group. A multivariate regression model in which the log-transformed PSA concentration was plotted against age and race was used to determine whether the PSA concentrations differed significantly according to race when we controlled for age. Receiver-operating-characteristic (ROC) curves in which the value for sensitivity was plotted against the false positive rate (1 minus the value for specificity) were generated for the white and black cohorts, both overall and within each 10-year age group. The area under the ROC curve was estimated according to the method of Hanley and McNeil.15 Population-based ROC curves for white men from Olmsted County, Minnesota, are included in the figures for comparison. In all the analyses, P values of less than 0.05 were considered to indicate statistical significance.
Results
Table 1Table 1
Distribution of Serum PSA Levels According to Race and Age Group among the Controls and Patients with Prostate Cancer Studied at Walter Reed Army Medical Center, 1991–1995. shows the distribution of serum PSA levels according to race, age, and status as a patient or control for each 10-year age group. In both racial groups the median serum PSA level among the controls was 1.3 ng per milliliter. The mean values differed significantly, however, and the difference persisted after adjustment for age (mean PSA level in blacks, 2.6 ng per milliliter; in whites, 1.9 ng per milliliter; P<0.001). There was more variation with increasing age among blacks than among whites, as shown by the differences in the interquartile range (the range between the 25th and 75th percentiles). Over the entire range of ages, the serum PSA concentrations correlated directly with age among the controls in each racial group (r = 0.40 for blacks and 0.34 for whites; P<0.001 for both). The distribution of serum PSA concentrations was shifted to a higher level in the black men than in the whites; the distribution in the whites was nearly identical to that reported by Oesterling et al.8 (Figure 1Figure 1Serum Concentrations of Prostate-Specific Antigen as a Function of Age and Race in Men with No Clinical Evidence of Prostate Cancer.).Table 2Table 2
Sensitivity and Specificity of the Serum PSA Test According to Race, Age Group, and Serum PSA Level in the Entire Study Population. shows the sensitivity and specificity of the serum PSA test in diagnosing prostate cancer according to race, age, and PSA level. When the 95th percentile in the black controls (Table 1) was used as a cutoff (with specificity maintained at 95 percent), sensitivity was markedly reduced to 67, 52, and 28 percent for men in their 50s, 60s, and 70s, respectively (data not shown). The traditional cutoff of 4.0 ng per milliliter had a sensitivity of 48 percent for men in their 40s and nearly 99 percent for men in their 70s.The trade-offs in sensitivity and specificity in the study populations are shown in the ROC curves in Figure 2AFigure 2
Receiver-Operating-Characteristic Curves of Sensitivity Plotted against 100 minus Specificity for Men 40 to 79 Years of Age., Figure 2B, Figure 2C, and Figure 2D. The area under the curve shows the probability that the PSA level will be higher in a randomly selected patient in this population than in a randomly selected control. The more the area under the curve approaches 1.0 (i.e., the more the ROC curve approaches the upper left-hand corner), the greater the predictive power of the screening test. Overall, serum PSA levels are valuable in discriminating between the absence and presence of prostate cancer; the areas under the ROC curves for blacks are 0.98 for men in their 40s, 0.94 for men in their 50s, 0.91 for men in their 60s, and 0.92 for men in their 70s. Among whites, the corresponding areas under the ROC curves are 0.99, 0.98, 0.97, and 0.96 — very similar to the areas under the population-based ROC curves for the men from Olmsted County (unpublished data).Discussion
We found that serum PSA levels in black men without prostate cancer increase with age, as they do in whites. The black men we studied had higher PSA values, however, and their PSA levels were more widely distributed, particularly among older men. As a result, the 95th percentiles for black men were significantly higher than those for whites. Therefore, if the usual 95th percentiles were used in a black population, more than 40 percent of cases of prostate cancer would go unidentified. This poor sensitivity is especially disturbing because black men are at higher risk for prostate cancer than white men.2,16
The reason for the higher PSA values in black men is unknown. In our prior investigation of PSA levels in men with newly diagnosed prostate cancer, black patients with prostate cancer had higher PSA values even when we adjusted for age, tumor grade, and the clinical stage of disease. Tumor volume, which was greater in black men, accounted for some, but not all, of the racial difference in PSA levels.14 In the population without clinical evidence of prostate cancer described here, we also found racial differences in PSA levels. Even though we excluded patients with known prostate cancer and those with elevated levels of PSA (>4.0 ng per milliliter) who did not undergo transrectal ultrasonography or prostate biopsy, it is possible that an excess of high-grade prostatic intraepithelial neoplasia among the black men may have contributed to the difference in serum PSA levels. A study of black and white men at autopsy showed a significantly higher prevalence of high-grade prostatic intraepithelial neoplasia, but not frank carcinoma, among the black men 30 to 59 years of age.17,18 Nevertheless, the effect of high-grade prostatic intraepithelial neoplasia alone on serum PSA values is unknown. Higher levels of testosterone in young black men as compared with a similar group of whites19 suggest that higher levels of stimulation by androgens may also account for racial differences in PSA levels.
A number of issues deserve comment. First, we included as case patients all the men with prostate cancer who had elevated levels of PSA before biopsy, instead of selecting only those in whom such levels were indications for biopsy. This decision did not materially affect the results, since only 7 percent of blacks with prostate cancer had an abnormal digital rectal examination as the only indicator for prostate biopsy. Furthermore, less than 0.5 percent of each racial group underwent biopsy solely because of symptoms. In our control group, we assumed that two separate biopsies could rule out more than 95 percent of cases of prostate cancer20 and that a PSA concentration below 4.0 ng per milliliter combined with a normal digital rectal examination indicated a minimal likelihood of prostate cancer, obviating the need for further evaluation. The latter assumption may have increased the “normal” reference ranges for PSA in men under the age of 50, whereas the former assumption could have increased the values in the older control group. Resolving these uncertainties would require prostate biopsies of all the study patients, coupled with long-term follow-up to rule out the future development of prostate cancer. Our study had no known selection bias, because in the military all eligible patients have access to care without regard to health insurance. PSA levels in our white population (tested with the IMx assay) were similar to those in the Olmsted County population (tested with the Tandem-R assay [Hybritech]),8 suggesting that serum PSA levels were not influenced by the choice of assay technique.
With areas under the ROC curve of 0.91 for black men and 0.94 for white men — as compared with 0.70 for Papanicolaou smears for cervical cancer,21 for example — the PSA assay is clearly valuable as a screening test. A caveat in this type of analysis, however, is that sensitivity and specificity may not be weighted equally when the test is applied clinically. In a given patient it is important to take into account associated risk factors and coexisting conditions and the patient's determination and desire to undergo further evaluation. The cutoff levels used with younger men and men at increased risk for prostate cancer should emphasize sensitivity, whereas the levels used in men more than 70 years old, men with a limited life expectancy, or both should emphasize specificity. Because these judgments vary from person to person, applying reference ranges blindly in clinical practice is inappropriate. With this in mind, we propose that ranges be used only as guides, with the decision to evaluate a patient's condition further being based on his desires and medical history.
On the basis of our data, reference ranges for black men that give sensitivity priority over specificity by maintaining a sensitivity of 95 percent are as follows: 0 to 2.0 ng of PSA per milliliter for men in their 40s, 0 to 4.0 ng per milliliter for men in their 50s, 0 to 4.5 ng per milliliter for men in their 60s, and 0 to 5.5 ng per milliliter for men in their 70s (Table 3Table 3
Age-Specific Reference Ranges for the PSA Test, Based on the 5th Percentile of the Distribution of PSA Levels in the Patients, According to Race.). These reference ranges give superior sensitivity with an acceptable trade-off in specificity as compared with the standard range (0.0 to 4.0 ng of PSA per milliliter), with age-specific reference ranges based on values obtained in whites,8 and with the 95th percentiles of the distribution of PSA levels in black men without prostate cancer. Sensitivity is improved the most among men in their 40s (from 49 percent for the standard range and 87 percent for the age-specific reference ranges previously reported8). Using a similar approach in white men would produce reference ranges of 0 to 2.5 ng per milliliter for men in their 40s and 0 to 3.5 ng per milliliter for men in their 50s, 60s, and 70s (Table 3).In conclusion, serum PSA concentrations in black men both with and without clinical evidence of prostate cancer are significantly higher than those in similar white men. The age-specific reference ranges derived from the 95th percentiles of the distribution of PSA levels in a large black population without prostate cancer are much higher than those derived from similar whites and are of limited clinical value. Nonetheless, serum PSA screening is a powerful tool for the detection of prostate cancer in both blacks and whites, and when properly applied on an individual basis, the use of age-specific reference ranges can improve the clinical value of such screening. Our age-specific reference ranges (Table 3) indicate values for clinicians that maximize the detection of cancer in each 10-year period between the ages of 40 and 79 years.
Supported by a Clinical Research Grant from the Diagnostics Division, Abbott Laboratories; by a grant from the Center for Prostate Disease Research, U.S. Army Medical Research and Development Command; and by the Henry M. Jackson Foundation for the Advancement of Military Medicine.
The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the U.S. Army or the Department of Defense.
We are indebted to Ms. Sondra Buehler and Ms. Renee D. Mooneyhan for their assistance in the preparation of the manuscript and to Mr. Hugh A. Schmidt for his assistance with the data collection.
Source Information
From the Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, D.C. (T.O.M., D.G.M., J.W.M.); the Sections of Clinical Epidemiology (S.J.J.) and Biostatistics (D.J.J.), Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minn.; and the Department of Surgery and Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Md. (W.F.M., D.G.M., J.W.M.).
Address reprint requests to Dr. Moul at the Department of Surgery, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814-4799.
- References
References
1
Parker SL ,Tong T ,Bolden S ,Wingo PA . Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27
CrossRef | Web of Science | Medline2
Morton RA Jr . Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994;44:637-645
CrossRef | Web of Science | Medline3
Mettlin C ,Jones G ,Averette H ,Gusberg SB ,Murphy GP . Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993;43:42-46
CrossRef | Web of Science | Medline4
Early detection of prostate cancer and use of transrectal ultrasound. In: American Urological Association 1992 policy statement book. Baltimore: American Urological Association, 1992:4.20.
5
Stamey TA ,Yang N ,Hay AR ,McNeal JE ,Freiha FS ,Redwine E . Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916
Full Text | Web of Science | Medline6
Walsh PC . Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med 1993;119:948-949
Web of Science | Medline7
Catalona WJ ,Richie JP ,Ahmann FR , et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290
Web of Science | Medline8
Oesterling JE ,Jacobsen SJ ,Chute CG , et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993;270:860-864
CrossRef | Web of Science | Medline9
Dalkin BL ,Ahmann FR ,Kopp JB . Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993;150:1837-1839
Web of Science | Medline10
Anderson JR ,Strickland D ,Corbin D ,Byrnes JA ,Zweiback E . Age-specific reference ranges for serum prostate-specific antigen. Urology 1995;46:54-57
CrossRef | Web of Science | Medline11
DeAntoni EP ,Crawford ED . Prostate cancer awareness week: education, service, and research in a community setting. Cancer 1995;75:Suppl:1874-1879
CrossRef | Web of Science12
el-Galley RES ,Petros JA ,Sanders WH , et al. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 1995;46:200-204
CrossRef | Web of Science | Medline13
Oesterling JE ,Kumamoto Y ,Tsukamoto T , et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75:347-353
CrossRef | Medline14
Moul JW ,Sesterhenn IA ,Connelly RR , et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995;274:1277-1281
CrossRef | Web of Science | Medline15
Hanley JA ,McNeil BJ . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
Web of Science | Medline16
Pienta KJ ,Demers R ,Hoff M ,Kau TY ,Montie JE ,Severson RK . Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tricounty area, 1973 to 1987. Urology 1995;45:93-102
CrossRef | Web of Science | Medline17
Sakr WA ,Haas GP ,Cassin BF ,Pontes JE ,Crissman JD . The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385
Web of Science | Medline18
Sakr WA ,Crignon DJ ,Haas GP . Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:838-841
CrossRef | Web of Science | Medline19
Ross RK ,Bernstein L ,Lobo RA , et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889
CrossRef | Web of Science | Medline20
Keetch DW ,Catalona WJ ,Smith DS . Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-1574
Web of Science | Medline21
Fahey MT ,Irwig L ,Macaskill P . Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-689
Web of Science | Medline
- Citing Articles (166)
Citing Articles
1
F. Giton, J. Fiet, J.-N. Cornu, O. Cussenot, A. Belanger, S. Urien, A. Oliva, P. Blanchet, L. Multigner. (2011) Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry. European Journal of Endocrinology 165:6, 917-924
CrossRef2
Marwan Hailan, Usama Nihad Rifat. (2011) Age-specific reference ranges of serum prostate-specific antigen in Iraqi men. Arab Journal of Urology
CrossRef3
Maureen E. O'Rourke. (2011) The Prostate-Specific Antigen Screening Conundrum: Examining the Evidence. Seminars in Oncology Nursing 27:4, 251-259
CrossRef4
Jonathan L. Wright, Daniel W. Lin, Janet L. Stanford. (2011) The effect of demographic and clinical factors on the relationship between BMI and PSA levels. The Prostate 71:15, 1631-1637
CrossRef5
Ping Tang, Wei Du, Keji Xie, Xiangrong Deng, Jingao Fu, Hui Chen, Wenjun Yang. (2011) Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. Urologic Oncology: Seminars and Original Investigations
CrossRef6
Yu-Kuan Lin, Lori Gettle, Jay D. Raman. (2011) Variable Prostate-specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Care Medical Center. Urology 78:2, 244-248
CrossRef7
Ganna Chornokur, Kyle Dalton, Meghan E. Borysova, Nagi B. Kumar. (2011) Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. The Prostate 71:9, 985-997
CrossRef8
Bob Djavan, Amir Kazzazi, Lori Dulabon, Markus Margreiter, Alexander Farr, Markus Johannes Handl, Herbert Lepor. (2011) Diagnostic Strategies for Prostate Cancer. European Urology Supplements 10:3, e26-e37
CrossRef9
Bob Djavan. (2011) Screening for Prostate Cancer: Practical Analysis of the ESRPC and PLCO Trials. European Urology 59:3, 365-369
CrossRef10
Joel Yarney, Verna Vanderpuye, James Mensah. (2011) Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men. Urologic Oncology: Seminars and Original Investigations
CrossRef11
LiXin Hua, Di Qiao, Bin Xu, NingHan Feng, Gong Cheng, JieXiu Zhang, NingHong Song, Wei Zhang, Jie Yang, JianGang Chen, YuanGeng Sui, HongFei Wu. (2011) Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China. Medical Oncology 28:1, 357-364
CrossRef12
Sudip Nanda, Tanujit Dey, Rudolph E. Gulstrand, Daniel Cudnik, Harold S. Haller. (2011) Fall Risk Assessment in Geriatric-Psychiatric Inpatients to Lower Events (FRAGILE). Journal of Gerontological Nursing 37:2, 22-30
CrossRef13
Ping Tang, Wei Du, Keji Xie, Jingao Fu, Hui Chen, Wenjun Yang, Judd W. Moul. (2011) Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. The Prostaten/a-n/a
CrossRef14
Ping Tang, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, David M. Albala, Craig F. Donatucci, Judd W. Moul. (2010) Prostate-specific Antigen–based Risk-adapted Discontinuation of Prostate Cancer Screening in Elderly African American and Caucasian American Men. Urology 76:5, 1058-1062
CrossRef15
K. J. Vega, T. Langford-Legg, J. Watts, C. Lambiase, L. R. Lambiase, M. M. Jamal. (2010) Reflux episodes are similar in healthy African Americans and non-Hispanic whites. Diseases of the Esophagus 23:8, 609-612
CrossRef16
C. Börgermann, H. Loertzer, P. Hammerer, P. Fornara, M. Graefen, H. Rübben. (2010) Probleme, Zielsetzung und Inhalt der Früherkennung beim Prostatakarzinom. Der Urologe 49:2, 181-189
CrossRef17
Sang-Hyun Hwang, Heung-Bum Oh, Tina Pyo, Hyun-Jin Lee, Kwan Jeh Lee. (2010) Study on Interpretation of Quantitative Results of Prostate-specific Antigen Using Information Theory. The Korean Journal of Laboratory Medicine 30:4, 357
CrossRef18
Ping Tang, Leon Sun, Matthew A. Uhlman, Cary N. Robertson, Thomas J. Polascik, Judd W. Moul. (2010) Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men : PSA VELOCITY RISK-ADAPTED SCREENING. BJU Internationalno
CrossRef19
J.A. Gelpi-Méndez, E. Gómez-Fernández, J. Martín-Barallat, M.V. Cortés-Arcas, J.V. Monsonis-Artero, A. Calvo-Mora. (2010) Reference values of prostate specific antigen (PSA) in 63926 workers without prostatic symptoms who participated in prostate screening cancer developed by the Ibermutuamur Prevention Society in 2006. Actas Urológicas Españolas (English Edition) 34:8, 669-676
CrossRef20
Kirsten L. Greene, Peter C. Albertsen, Richard J. Babaian, H. Ballentine Carter, Peter H. Gann, Misop Han, Deborah Ann Kuban, A. Oliver Sartor, Janet L. Stanford, Anthony Zietman, Peter Carroll. (2009) Prostate Specific Antigen Best Practice Statement: 2009 Update. The Journal of Urology 182:5, 2232-2241
CrossRef21
C. Börgermann, H. Loertzer, H.-J. Luboldt, P. Hammerer, P. Fornara, M. Graefen, H. Rübben. (2009) PSA – Quo vadis?. Der Urologe 48:9, 1008-1017
CrossRef22
Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi, Vincent Cloutier, Claudio Jeldres, Shahrokh F. Shariat, Alain Duclos, Philippe Arjane, Fred Saad, Francesco Montorsi, Pierre I. Karakiewicz. (2009) Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort. Urology 73:6, 1323-1327
CrossRef23
Neil E. Fleshner, Nathan Lawrentschuk. (2009) Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers. Urology 73:5, S21-S27
CrossRef24
Kenneth J. Pienta. (2009) Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later. Urology 73:5, S11-S20
CrossRef25
Daniel E. Soto, Rebecca R. Andridge, Jeremy M.G. Taylor, Patrick W. McLaughlin, Howard M. Sandler, Charlie C. Pan. (2008) Predicting Biochemical Failure and Overall Survival Through Intratherapy PSA Changes During Definitive External Beam Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 72:5, 1408-1415
CrossRef26
Christopher S. Elliott, Rajesh Shinghal, Joseph C. Presti. (2008) Racial Variations in the Performance of Prostate Specific Antigen and Prostate Specific Antigen Density in the Era of Extended Prostate Biopsy Schemes. The Journal of Urology 180:4, 1318-1324
CrossRef27
Judd W Moul, Vladimir Mouraviev. (2008) Should elderly men be screened for prostate cancer?. Aging Health 4:5, 443-446
CrossRef28
K. J. VEGA, T. LANGFORD-LEGG, M. M. JAMAL. (2008) Ethnic variation in lower oesophageal sphincter pressure and length. Alimentary Pharmacology & Therapeutics 28:5, 655-659
CrossRef29
M.H. Winkler, E.K. Mayer, A. Carter, E. Kulinskaya, J.S.A. Green. (2008) Age-specific PSA reference values based on a screening population of British men. British Journal of Medical and Surgical Urology 1:1, 25-30
CrossRef30
Vladimir Mouraviev, Gloria Broadwater, Leon Sun, Janice M. Mayes, Judd W. Moul, Thomas J. Polascik. (2008) Can Prostate-Specific Antigen and Prostate-Specific Antigen Velocity Be Used for Prostate Cancer Screening in Men Older Than 70 Years?. Urology 71:6, 1020-1023
CrossRef31
Hans Lilja, David Ulmert, Andrew J. Vickers. (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews Cancer 8:4, 268-278
CrossRef32
Badrinath R. Konety, Victoria J. Sharp, Hrishikesh Raut, Richard D. Williams. (2008) Screening and Management of Prostate Cancer in Elderly Men: The Iowa Prostate Cancer Consensus. Urology 71:3, 511-514
CrossRef33
Amanda Reed, Donna P. Ankerst, Brad H. Pollock, Ian M. Thompson, Dipen J. Parekh. (2007) Current Age and Race Adjusted Prostate Specific Antigen Threshold Values Delay Diagnosis of High Grade Prostate Cancer. The Journal of Urology 178:5, 1929-1932
CrossRef34
H B Shim, S E Lee, H K Park, J H Ku. (2007) Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer. Prostate Cancer and Prostatic Diseases 10:3, 250-255
CrossRef35
Alexandre de la Taille. (2007) Progensa™ PCA3 test for prostate cancer detection. Expert Review of Molecular Diagnostics 7:5, 491-497
CrossRef36
Felix K.-H. Chun, Georg C. Hutterer, Paul Perrotte, Andrea Gallina, Luc Valiquette, Francois Benard, Michael McCormack, Alberto Briganti, Constantin Ionescu, Claudio Jeldres, Jean-Pierre Guay, Fred Saad, Pierre I. Karakiewicz. (2007) Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU International 100:1, 37-41
CrossRef37
John C. Mavropoulos, Alan W. Partin, Christopher L. Amling, Martha K. Terris, Christopher J. Kane, William J. Aronson, Joseph C. Presti, Leslie A. Mangold, Stephen J. Freedland. (2007) Do Racial Differences in Prostate Size Explain Higher Serum Prostate-Specific Antigen Concentrations Among Black Men?. Urology 69:6, 1138-1142
CrossRef38
Stéphane Mallick, Marc Romana, Pascal Blanchet, Luc Multigner. (2007) GSTM1 and GSTT1 Polymorphisms and the Risk of Prostate Cancer in a Caribbean Population of African Descent. Urology 69:6, 1165-1169
CrossRef39
Stacy Loeb, Kimberly A. Roehl, William J. Catalona, Robert B. Nadler. (2007) Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men. The Journal of Urology 177:3, 899-902
CrossRef40
M. N. G. Battikhi, I. Hussein. (2007) Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. International Urology and Nephrology 38:3-4, 559-564
CrossRef41
Kenneth J. Vega, Ehab Rabaa, M. Mazen Jamal. (2007) Lower Esophageal Sphincter Pressure and Distal Esophageal Body Function Between Hispanic Americans and Non-Hispanic Whites are Equivalent. Journal of Clinical Gastroenterology 41:2, 141-144
CrossRef42
Andreas P. Berger, Martina Deibl, Alexander Strasak, Jasmin Bektic, Alexandre E. Pelzer, Helmut Klocker, Hannes Steiner, Gernot Fritsche, Georg Bartsch, Wolfgang Horninger. (2007) Large-Scale Study of Clinical Impact of PSA Velocity: Long-Term PSA Kinetics as Method of Differentiating Men with from Those without Prostate Cancer. Urology 69:1, 134-138
CrossRef43
Jay H. Fowke, Lisa B. Signorello, Sam S. Chang, Charles E. Matthews, Maciej S. Buchowski, Michael S. Cookson, Flora M. Ukoli, William J. Blot. (2006) Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 107:10, 2361-2367
CrossRef44
Gerald Hoke, William Baker, Carlton Barnswell, James Bennett, Rodney Davis, Terry Mason, Walter Rayford. (2006) Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia. Urology 68:5, 924-930
CrossRef45
Andreas P. Berger, Martina Deibl, Alexander Strasak, Jasmin Bektic, Alexandre Pelzer, Hannes Steiner, Robert Spranger, Gernot Fritsche, Georg Bartsch, Wolfgang Horninger. (2006) Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: Results from a screening population. Urology 68:5, 1067-1071
CrossRef46
Hossein Sadeghi-Nejad, Marc Simmons, George Dakwar, Vikram Dogra. (2006) Controversies in Transrectal Ultrasonography and Prostate Biopsy. Ultrasound Quarterly 22:3, 169-175
CrossRef47
Katharine McGreevy, Keith Rodgers, Stuart Lipsitz, Nabil Bissada, David Hoel. (2006) Impact of race and baseline PSA on longitudinal PSA. International Journal of Cancer 118:7, 1773-1776
CrossRef48
Rinaa S. Punglia, Anthony V. D'Amico, William J. Catalona, Kimberly A. Roehl, Karen M. Kuntz. (2006) Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 106:7, 1507-1513
CrossRef49
L L Xu, C Sun, G Petrovics, M Makarem, B Furusato, W Zhang, I A Sesterhenn, D G McLeod, L Sun, J W Moul, S Srivastava. (2006) Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer and Prostatic Diseases 9:1, 56-61
CrossRef50
T. Malati, G. Rajani Kumari, P. V. L. N. Murthy, Ch. Ram Reddy, B. Surya Prakash. (2006) Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian Journal of Clinical Biochemistry 21:1, 34-40
CrossRef51
Stacy Loeb, Kimberly A. Roehl, Jo Ann V. Antenor, William J. Catalona, Brian K. Suarez, Robert B. Nadler. (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67:2, 316-320
CrossRef52
Alan R. Kristal, Chen Chi, Catherine M. Tangen, Phyllis J. Goodman, Ruth Etzioni, Ian M. Thompson. (2006) Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106:2, 320-328
CrossRef53
JA HYEON KU. (2006) Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU International 97:1, 69-72
CrossRef54
M. Sheikh, O. Al-Saeed, E.O. Kehinde, T. Sinan, J. T. Anim, Y. Ali. (2005) Utility of Volume Adjusted Prostate Specific Antigen Density in the Diagnosis of Prostate Cancer in Arab Men. International Urology and Nephrology 37:4, 721-726
CrossRef55
TAKASHI KOBAYASHI, KENJI MITSUMORI, TAKASHI KAWAHARA, KOJI NISHIZAWA, KEIJI OGURA, YOSHIHIRO IDE. (2005) Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL. International Journal of Urology 12:11, 969-975
CrossRef56
ALICE S. WHITTEMORE, PIERA M. CIRILLO, DAVID FELDMAN, BARBARA A. COHN. (2005) PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANS. The Journal of Urology 174:3, 872-876
CrossRef57
Judd W. Moul. (2005) A discussion of general prostate cancer screening versus targeted diagnosis in younger men. Current Prostate Reports 3:3, 99-111
CrossRef58
TAKASHI KOBAYASHI, HIDEFUMI KINOSHITA, KOJI NISHIZAWA, KENJI MITSUMORI, OSAMU OGAWA, TOSHIYUKI KAMOTO. (2005) Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics. International Journal of Urology 12:8, 733-738
CrossRef59
Andreas P. Berger, Martina Deibl, Hannes Steiner, Jasmin Bektic, Alexandre Pelzer, Robert Spranger, Helmut Klocker, Georg Bartsch, Wolfgang Horninger. (2005) Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. The Prostate 64:3, 240-245
CrossRef60
J. C. Routh, B. C. Leibovich. (2005) Adenocarcinoma of the Prostate: Epidemiological Trends, Screening, Diagnosis, and Surgical Management of Localized Disease. Mayo Clinic Proceedings 80:7, 899-907
CrossRef61
Jeremy B. Shelton, Daniel A. Barocas, Frances Conway, Kathleen Hart, Kinloch Nelson, Lee Richstone, Ricardo R. Gonzalez, Jay D. Raman, Douglas S. Scherr. (2005) Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies. Urology 65:5, 931-936
CrossRef62
Takashi Kobayashi, Toshiyuki Kamoto, Koji Nishizawa, Kenji Mitsumori, Keiji Ogura, Yoshihiro Ide. (2005) Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL. BJU International 95:6, 761-765
CrossRef63
Stephen J. Freedland, William B. Isaacs. (2005) Explaining racial differences in prostate cancer in the United States: Sociology or biology?. The Prostate 62:3, 243-252
CrossRef64
Allen C. Chen, Richard J. MacChia, Francine Conway, Carol Magai, Manisha Desai, Alfred I. Neugut. (2004) Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: A pilot study. Urology 64:3, 522-527
CrossRef65
Amit Gupta, Claus G Roehrborn. (2004) Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example. Urology 64:1, 106-111
CrossRef66
C.R. Ritch, C.B. Brendler, R.L. Wan, K.E. Pickett, M.H. Sokoloff. (2004) Relationship of erythrocyte membrane polyunsaturated fatty acids and prostate-specific antigen levels in Jamaican men. BJU International 93:9, 1211-1215
CrossRef67
RICHARD E. LINK, SHAHROKH F. SHARIAT, CUONG V. NGUYEN, ANITA FARR, ARMIN D. WEINBERG, RONALD A. MORTON, BARBARA RICHARDSON, DAVID BERNARD, KEVIN M. SLAWIN. (2004) VARIATION IN PROSTATE SPECIFIC ANTIGEN RESULTS FROM 2 DIFFERENT ASSAY PLATFORMS: CLINICAL IMPACT ON 2,304 PATIENTS UNDERGOING PROSTATE CANCER SCREENING. The Journal of Urology 171:6, 2234-2238
CrossRef68
Carter, H. Ballentine, . (2004) Prostate Cancers in Men with Low PSA Levels — Must We Find Them?. New England Journal of Medicine 350:22, 2292-2294
Full Text69
Dalin He, Mingzhu Wang, Xingfa Chen, Zhongwei Gao, Hui He, Haiyen E Zhau, Wusheng Wang, Leland W.K Chung, Xunyi Nan. (2004) Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy chinese male population. Urology 63:4, 722-726
CrossRef70
Clareann H Bunker, Alan L Patrick, Iva Miljkovic-Gacic, Badrinath R Konety, Andrew Belle, Jean Robert Richard, Rajiv Dhir. (2004) Prostate cancer screening parameters in a high-risk African-Caribbean population. Urology 63:4, 737-741
CrossRef71
S.R. Denmeade, J.T. Isaacs. (2004) The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU International 93:s1, 10-15
CrossRef72
Robin T. Vollmer, MD. (2004) Race and the Linkage Between Serum Prostate-Specific Antigen and Prostate Cancer A Study of American Veterans. American Journal of Clinical Pathology 122:3, 338-344
CrossRef73
Sang Eun Lee. (2004) The Diagnostic Value of Prostate-specific Antigen and the Necessity of Routine Laboratory Examination for Early Detection. Journal of the Korean Medical Association 47:5, 403
CrossRef74
T. Malati, G. Rajani Kumari. (2004) Racial and ethnic variation of PSA in global population: Age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian Journal of Clinical Biochemistry 19:1, 132-137
CrossRef75
Ian D Cockshott. (2004) Bicalutamide. Clinical Pharmacokinetics 43:13, 855-878
CrossRef76
Pankaj Kalra, Joanna Togami, Gaurav Bansal B.S., Alan W. Partin, Michael K. Brawer, Richard J. Babaian, Lawrence S. Ross, Craig S. Niederberger. (2003) A neurocomputational model for prostate carcinoma detection. Cancer 98:9, 1849-1854
CrossRef77
Andreas P Berger, Carol Cheli, Ronald Levine, Helmut Klocker, Georg Bartsch, Wolfgang Horninger. (2003) Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. Urology 62:5, 840-844
CrossRef78
Punglia, Rinaa S., D'Amico, Anthony V., Catalona, William J., Roehl, Kimberly A., Kuntz, Karen M., . (2003) Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen. New England Journal of Medicine 349:4, 335-342
Full Text79
S. D. Cramer, B.-L. Chang, A. Rao, G. A. Hawkins, S. L. Zheng, W. N. Wade, R. T. Cooke, L. N. Thomas, E. R. Bleecker, W. J. Catalona, D. A. Sterling, D. A. Meyers, J. Ohar, J. Xu. (2003) Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels. JNCI Journal of the National Cancer Institute 95:14, 1044-1053
CrossRef80
S.M Gueye, C.M Zeigler-Johnson, T Friebel, E Spangler, M Jalloh, S MacBride, S.B Malkowicz, T.R Rebbeck. (2003) Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men. Urology 61:5, 987-992
CrossRef81
Benjamin Martin, Carol Cheli, Steven Pollard, Jerry Sullivan, Jack Goodman, Mohan Kokatnur, Maria Ward, Laraine Martin, Don Mercante, Walter Rayford. (2003) Similar age-specific PSA, complexed PSA, and percent cPSA levels among African-American and white men of southern Louisiana. Urology 61:2, 375-379
CrossRef82
GURAM KARAZANASHVILI, PER-ANDERS ABRAHAMSSON. (2003) Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate Cancer. The Journal of Urology 169:2, 445-457
CrossRef83
Robert W Veltri, M.Craig Miller, Gerard J O’dowd, Alan W Partin. (2002) Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 60:4, 47-52
CrossRef84
Ja Hyeon Ku, Jae Ouk Ahn, Chang Ho Lee, Nam Kyu Lee, Young Ho Park, Seok Soo Byun, Cheol Kwak, Sang Eun Lee. (2002) Distribution of serum prostate-specific antigen in healthy korean men: influence of ethnicity. Urology 60:3, 475-479
CrossRef85
PETER H. GANN, JING MA, WILLIAM J. CATALONA, MEIR J. STAMPFER. (2002) Strategies Combining Total and Percent Free Prostate Specific Antigen for Detecting Prostate Cancer: A Prospective Evaluation. The Journal of Urology2427-2434
CrossRef86
PETER H. GANN, JING MA, WILLIAM J. CATALONA, MEIR J. STAMPFER. (2002) Strategies Combining Total and Percent Free Prostate Specific Antigen for Detecting Prostate Cancer: A Prospective Evaluation. The Journal of Urology 167:6, 2427-2434
CrossRef87
Jackson E. Fowler, Steven A. Bigler, Paul B. Farabaugh. (2002) Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer 94:6, 1661-1667
CrossRef88
Jackson E. Fowler, Steven A. Bigler. (2002) Racial differences in prostate carcinogenesis. Urologic Clinics of North America 29:1, 183-191
CrossRef89
A A Wadee, R Kuschke, Y Botha, G A Jamieson, A R P Walker, A S L Kakembo, H H Vorster. (2002) Low serum prostate-specific antigen levels in elderly rural African men at very low risk of prostate cancer. European Journal of Cancer Prevention 11:1, 63-65
CrossRef90
Peter S Bunting. (2002) Screening for prostate cancer with prostate-specific antigen: beware the biases. Clinica Chimica Acta 315:1-2, 71-97
CrossRef91
Steven J Jacobsen, Cynthia J Girman, Michael M Lieber. (2001) Natural history of benign prostatic hyperplasia. Urology 58:6, 5-16
CrossRef92
Abelardo Errejon, E. David Crawford, Judith Dayhoff, Colin O'Donnell, Ashutosh Tewari, James Finkelstein, Eduard J. Gamito. (2001) Use Of Artificial Neural Networks In Prostate Cancer. Molecular Urology 5:4, 153-158
CrossRef93
H.Ballentine Carter. (2001) Rationale for earlier and less frequent prostate cancer screening. Urology 58:5, 639-641
CrossRef94
Edward P Gelmann, David Chia, Paul F Pinsky, Gerald L Andriole, E.David Crawford, Douglas Reding, Richard B Hayes, Barnett S Kramer, David L Woodrum, John K Gohagan, David L Levin. (2001) Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology 58:4, 561-566
CrossRef95
Junyong Fang, E.Jeffrey Metter, Patricia Landis, Daniel W Chan, Christopher H Morrell, H.Ballentine Carter. (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58:3, 411-416
CrossRef96
Jackson E. Fowler, Steven A. Bigler, Cynthia Lynch, Shandra S. Wilson, Paul B. Farabaugh. (2001) Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. Cancer 91:7, 1291-1296
CrossRef97
Peter R Carroll. (2001) Serum prostate-specific antigen for prostate cancer early detection: total, free, age- stratified, or complexed?. Urology 57:4, 591-593
CrossRef98
Judd W Moul. (2001) Prostate-specific antigen–enhanced testing and risk stratification for chemoprevention trials. Urology 57:4, 174-177
CrossRef99
Stephen J Freedland, Frederick Dorey, William J Aronson. (2001) Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57:3, 476-480
CrossRef100
Steven G Heeringa, Kirsten H Alcser, Kay Doerr, Myla Strawderman, Kathleen Cooney, Bruce Medbery, David Schottenfeld. (2001) Potential selection bias in a community-based study of PSA levels in African-American men. Journal of Clinical Epidemiology 54:2, 142-148
CrossRef101
Kathleen A Cooney, Myla S Strawderman, Kirk J Wojno, Kay M Doerr, Adrienne Taylor, Kirsten H Alcser, Steven G Heeringa, Jeremy M.G Taylor, John T Wei, James E Montie, David Schottenfeld. (2001) Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 57:1, 91-96
CrossRef102
JACKSON E. FOWLER, STEVEN A. BIGLER, PAUL B. FARABAUGH, SHANDRA S. WILSON. (2000) PROSTATE CANCER DETECTION IN BLACK AND WHITE MEN WITH ABNORMAL DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN LESS THAN 4 NG./ML.. The Journal of Urology1961-1963
CrossRef103
Sang Eun Lee, Cheol Kwak, Moon Soo Park, Chang Ho Lee, Weechang Kang, Seung-June Oh. (2000) Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology 56:6, 1007-1010
CrossRef104
CAROLYN V. SMITH, JOHN J. BAUER, ROGER R. CONNELLY, THOMAS SEAY, CHRISTOPHER KANE, JOHN FOLEY, J. BRANTLEY THRASHER, LEO KUSUDA, JUDD W. MOUL. (2000) PROSTATE CANCER IN MEN AGE 50 YEARS OR YOUNGER:. The Journal of Urology1964-1967
CrossRef105
JACKSON E. FOWLER, STEVEN A. BIGLER, PAUL B. FARABAUGH, SHANDRA S. WILSON. (2000) PROSTATE CANCER DETECTION IN BLACK AND WHITE MEN WITH ABNORMAL DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN LESS THAN 4 NG./ML.. The Journal of Urology 164:6, 1961-1963
CrossRef106
CAROLYN V. SMITH, JOHN J. BAUER, ROGER R. CONNELLY, THOMAS SEAY, CHRISTOPHER KANE, JOHN FOLEY, J. BRANTLEY THRASHER, LEO KUSUDA, JUDD W. MOUL. (2000) PROSTATE CANCER IN MEN AGE 50 YEARS OR YOUNGER:: A REVIEW OF THE DEPARTMENT OF DEFENSE CENTER FOR PROSTATE DISEASE RESEARCH MULTICENTER PROSTATE CANCER DATABASE. The Journal of Urology 164:6, 1964-1967
CrossRef107
David M Preston, Lynn I Levin, Debra J Jacobson, Steven J Jacobsen, Mark Rubertone, Eric Holmes, Gerald P Murphy, Judd W Moul. (2000) Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 56:5, 812-816
CrossRef108
Kazuto Ito, Takumi Yamamoto, Yutaka Kubota, Kazuhiro Suzuki, Yoshitatsu Fukabori, Kohei Kurokawa, Hidetoshi Yamanaka. (2000) Usefulness of age-specific reference range of prostate-specific antigen for japanese men older than 60 years in mass screening for prostate cancer. Urology 56:2, 278-282
CrossRef109
H.Ballentine Carter. (2000) A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology 55:6, 796-799
CrossRef110
JACKSON E. FOWLER, JANE SANDERS, STEVEN A. BIGLER, JEAN RIGDON, NIRMAL K. KILAMBI, SPENCER A. LAND. (2000) PERCENT FREE PROSTATE SPECIFIC ANTIGEN AND CANCER DETECTION IN BLACK AND WHITE MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN 2.5 TO 9.9 NG./ML.. The Journal of Urology 163:5, 1467-1470
CrossRef111
Judd W. Moul. (2000) Screening for prostate cancer in african americans. Current Urology Reports 1:1, 57-64
CrossRef112
Stephen J Freedland, Mark E Sutter, John Naitoh, Frederick Dorey, George S Csathy, William J Aronson. (2000) Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology 55:3, 387-390
CrossRef113
William J Catalona, Alan W Partin, Kevin M Slawin, Cathy K Naughton, Michael K Brawer, Robert C Flanigan, Jerome P Richie, Anup Patel, Patrick C Walsh, Peter T Scardino, Paul H Lange, Jean B deKernion, Paula C Southwick, Kathleen G Loveland, Robert E Parson, Gail H Gasior. (2000) Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 55:3, 372-376
CrossRef114
WEI ZHANG, ISABELL A. SESTERHENN, ROGER R. CONNELLY, F. K. MOSTOFI, JUDD W. MOUL. (2000) INFLAMMATORY INFILTRATE (PROSTATITIS) IN WHOLE MOUNTED RADICAL PROSTATECTOMY SPECIMENS FROM BLACK AND WHITE PATIENTS IS NOT AN ETIOLOGY FOR RACIAL DIFFERENCE IN PROSTATE SPECIFIC ANTIGEN. The Journal of Urology131
CrossRef115
P. Laguna, G. Alivizatos. (2000) Prostate specific antigen and benign prostatic hyperplasia. Current Opinion in Urology 10:1, 3-8
CrossRef116
William J. Aronson, Stephen J. Freeland. (2000) EDITORIAL: CAN WE LOWER THE MORTALITY RATE OF BLACK MEN WITH PROSTATE CANCER?. The Journal of Urology 163:1, 150-151
CrossRef117
William J. Aronson, Stephen J. Freeland. (2000) EDITORIAL: CAN WE LOWER THE MORTALITY RATE OF BLACK MEN WITH PROSTATE CANCER?. The Journal of Urology150
CrossRef118
I. J. POWELL, M. BANERJEE, M. NOVALLO, W. SAKR, D. GRIGNON, D. P. WOOD, J. E. PONTES. (2000) SHOULD THE AGE SPECIFIC PROSTATE SPECIFIC ANTIGEN CUTOFF FOR PROSTATE BIOPSY BE HIGHER FOR BLACK THAN FOR WHITE MEN OLDER THAN 50 YEARS?. The Journal of Urology146
CrossRef119
WEI ZHANG, ISABELL A. SESTERHENN, ROGER R. CONNELLY, F.K. MOSTOFI, JUDD W. MOUL. (2000) INFLAMMATORY INFILTRATE (PROSTATITIS) IN WHOLE MOUNTED RADICAL PROSTATECTOMY SPECIMENS FROM BLACK AND WHITE PATIENTS IS NOT AN ETIOLOGY FOR RACIAL DIFFERENCE IN PROSTATE SPECIFIC ANTIGEN. The Journal of Urology 163:1, 131-136
CrossRef120
I.J. POWELL, M. BANERJEE, M. NOVALLO, W. SAKR, D. GRIGNON, D.P. WOOD, J.E. PONTES. (2000) SHOULD THE AGE SPECIFIC PROSTATE SPECIFIC ANTIGEN CUTOFF FOR PROSTATE BIOPSY BE HIGHER FOR BLACK THAN FOR WHITE MEN OLDER THAN 50 YEARS?. The Journal of Urology 163:1, 146-149
CrossRef121
Ibrahim Abdalla, Paul Ray, Vera Ray, Florin Vaida, Srinivasan Vijayakumar. (1999) Racial Differences in Prostate-Specific Antigen Levels and Prostate-Specific Antigen Densities in Patients With Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials 22:6, 537
CrossRef122
Leslie A Kalish, John B McKinlay. (1999) Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology 54:6, 1022-1027
CrossRef123
Robert C. Burack, David P. Wood. (1999) SCREENING FOR PROSTATE CANCER. Medical Clinics of North America 83:6, 1423-1442
CrossRef124
James A Eastham, Robert May, John L Robertson, Oliver Sartor, Michael W Kattan. (1999) Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 54:4, 709-713
CrossRef125
CHRIS J. SOHAYDA, PATRICK A. KUPELIAN, KIMBERLY A. ALTSMAN, ERIC A. KLEIN. (1999) RACE AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. The Journal of Urology1331-1336
CrossRef126
CHRIS J. SOHAYDA, PATRICK A. KUPELIAN, KIMBERLY A. ALTSMAN, ERIC A. KLEIN. (1999) RACE AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. The Journal of Urology 162:4, 1331-1336
CrossRef127
Jackson E. Fowler, Steven A. Bigler. (1999) A prospective study of the serum prostate specific antigen concentrations and gleason histologic scores of black and white men with prostate carcinoma. Cancer 86:5, 836-841
CrossRef128
David G. Bostwick. (1999) What is the significance of race to prostate carcinoma?. Cancer 86:5, 735-737
CrossRef129
Shin Egawa, Kazumasa Matsumoto, Kazuho Suyama, Masatsugu Iwamura, Sadahito Kuwao, Shiro Baba. (1999) Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer 86:3, 463-469
CrossRef130
THOMAS J. POLASCIK, JOSEPH E. OESTERLING, ALAN W. PARTIN. (1999) PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING. The Journal of Urology 162:2, 293-306
CrossRef131
JUDD W. MOUL, ROGER R. CONNELLY, RENEE M. MOONEYHAN, WEI ZHANG, ISABELL A. SESTERHENN, F.K. MOSTOFI, DAVID G. McLEOD. (1999) RACIAL DIFFERENCES IN TUMOR VOLUME AND PROSTATE SPECIFIC ANTIGEN AMONG RADICAL PROSTATECTOMY PATIENTS. The Journal of Urology 162:2, 394-397
CrossRef132
Paul A. Godley. (1999) Prostate Cancer Screening: Promise and Peril-A Review. Cancer Detection <html_ent glyph="@amp;" ascii="&"/> Prevention 23:4, 316-324
CrossRef133
Jackson E Fowler, Steven A Bigler, Nirmal K Kilambi, Spencer A Land. (1999) Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology 53:6, 1175-1178
CrossRef134
William S Kubricht, Michael W Kattan, Oliver Sartor, James A Eastham. (1999) Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. Urology 53:3, 553-556
CrossRef135
Jackson E. Fowler, Steven A. Bigler, Nirmal K. Kilambi, Spencer A. Land. (1999) Results of transition zone biopsy in black and white men with suspected prostate cancer. Urology 53:2, 346-350
CrossRef136
Isaac J. Powell, Mousumi Banerjee, Wael Sakr, David Grignon, David P. Wood, Mary Novallo, Edson Pontes. (1999) Should African-American men be tested for prostate carcinoma at an earlier age than white men?. Cancer 85:2, 472-477
CrossRef137
H.Ballentine Carter, Jonathan I Epstein, Alan W Partin. (1999) Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53:1, 126-130
CrossRef138
Martin C Weinrich, Steven J Jacobsen, Sally P Weinrich, Judd W Moul, Joseph E Oesterling, Debra Jacobson, Rudolph Wise. (1998) Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 52:6, 967-973
CrossRef139
Christophe E. Iselin, James W. Box, Robin T. Vollmer, Lester J. Layfield, Judith E. Robertson, David F. Paulson. (1998) Surgical control of clinically localized prostate carcinoma is equivalent in African-American and White males. Cancer 83:11, 2353-2360
CrossRef140
DEBORAH S. SMITH, GUSTAVO F. CARVALHAL, DOUGLAS E. MAGER, ARNOLD D. BULLOCK, WILLIAM J. CATALONA. (1998) USE OF LOWER PROSTATE SPECIFIC ANTIGEN CUTOFFS FOR PROSTATE CANCER SCREENING IN BLACK AND WHITE MEN. The Journal of Urology 160:5, 1734-1738
CrossRef141
Alan W. Partin, Ray E. Stutzman. (1998) ELEVATED PROSTATE-SPECIFIC ANTIGEN, ABNORMAL PROSTATE EVALUATION ON DIGITAL RECTAL EXAMINATION, AND TRANSRECTAL ULTRASOUND AND PROSTATE BIOPSY. Urologic Clinics of North America 25:4, 581-589
CrossRef142
DEBORAH S. SMITH, GUSTAVO F. CARVALHAL, DOUGLAS E. MAGER, ARNOLD D. BULLOCK, WILLIAM J. CATALONA. (1998) USE OF LOWER PROSTATE SPECIFIC ANTIGEN CUTOFFS FOR PROSTATE CANCER SCREENING IN BLACK AND WHITE MEN. The Journal of Urology1734-1738
CrossRef143
Ronald A. Morton, Matthew N. Witte. (1998) Recent advances in basic and clinical prostate cancer research. Cancer 83:S8, 1730-1733
CrossRef144
Louis J.G. Gooren. (1998) Endocrine aspects of ageing in the male. Molecular and Cellular Endocrinology 145:1-2, 153-159
CrossRef145
B. DJAVAN, A.R. ZLOTTA, G. BYTTEBIER, S. SHARIAT, M. OMAR, C.C. SCHULMAN, M. MARBERGER. (1998) PROSTATE SPECIFIC ANTIGEN DENSITY OF THE TRANSITION ZONE FOR EARLY DETECTION OF PROSTATE CANCER. The Journal of Urology 160:2, 411-418
CrossRef146
B. DJAVAN, A. R. ZLOTTA, G. BYTTEBIER, S. SHARIAT, M. OMAR, C. C. SCHULMAN, M. MARBERGER. (1998) PROSTATE SPECIFIC ANTIGEN DENSITY OF THE TRANSITION ZONE FOR EARLY DETECTION OF PROSTATE CANCER. The Journal of Urology411-418
CrossRef147
CURTIS A. PETTAWAY, PATRICIA TRONCOSO, EDILBERTO I. RAMIREZ, DENNIS A. JOHNSTON, LINDA STEELHAMMER, R. JOSEPH BABAIAN. (1998) PROSTATE SPECIFIC ANTIGEN AND PATHOLOGICAL FEATURES OF PROSTATE CANCER IN BLACK AND WHITE PATIENTS. The Journal of Urology437-442
CrossRef148
CURTIS A. PETTAWAY, PATRICIA TRONCOSO, EDILBERTO I. RAMIREZ, DENNIS A. JOHNSTON, LINDA STEELHAMMER, R. JOSEPH BABAIAN. (1998) PROSTATE SPECIFIC ANTIGEN AND PATHOLOGICAL FEATURES OF PROSTATE CANCER IN BLACK AND WHITE PATIENTS: A COMPARATIVE STUDY BASED ON RADICAL PROSTATECTOMY SPECIMENS. The Journal of Urology 160:2, 437-442
CrossRef149
Joseph G. Borer, Joel Sherman, Michael C. Solomon, Marc W. Plawker, Richard J. Macchia. (1998) AGE SPECIFIC PROSTATE SPECIFIC ANTIGEN REFERENCE RANGES: POPULATION SPECIFIC. The Journal of Urology 159:2, 444-448
CrossRef150
Ibrahim Abdalla, Paul Ray, Vera Ray, Florin Vaida, Srinivasan Vijayakumar. (1998) Comparison of serum prostate-specific antigen levels and PSA density in african-american, white, and hispanic men without prostate cancer. Urology 51:2, 300-305
CrossRef151
Nobuaki Ohtake, Seiji Nakata, Jin Sato, Atsushi Koya, Kazuhisa Saruki, Jun Kurihara, Hiroaki Tsuji, Kyoichi Imai, Hidetoshi Yamanaka, Keiji Suzuki, Kiyonobu Tari. (1998) Significance of Measurement of Prostate Specific Antigen (PSA) in Familial Prostate Cancer Lines.. The Tohoku Journal of Experimental Medicine 184:1, 21-28
CrossRef152
Scott A. Optenberg, Joseph Y. Clark, Michael K. Brawer, Ian M. Thompson, Catherine R. Stein, Paul Friedrichs. (1997) Development of a decision-making tool to predict risk of prostate cancer: The cancer of the prostate risk index (CAPRI) test. Urology 50:5, 665-672
CrossRef153
Deborah S. Smith, Arnold D. Bullock, William J. Catalona. (1997) RACIAL DIFFERENCES IN OPERATING CHARACTERISTICS OF PROSTATE CANCER SCREENING TESTS. The Journal of Urology 158:5, 1861-1866
CrossRef154
(1997) EDITORIAL COMMENT. The Journal of Urology 158:1, 149
CrossRef155
Thomas D. Richardson, Joseph E. Oesterling. (1997) AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics of North America 24:2, 339-351
CrossRef156
Peter J. Littrup. (1997) Prostate cancer in African-American men. The Prostate 31:2, 139-141
CrossRef157
Ian M. Thompson. (1997) Editorial. The Journal of Urology919-920
CrossRef158
Joseph C. Presti, Regina Hovey, Vivek Bhargava, Peter R. Carroll, Katsuto Shinohara. (1997) Prospective Evaluation of Prostate Specific Antigen and Prostate Specific Antigen Density in the Detection of Carcinoma of the Prostate: Ethnic Variations. The Journal of Urology 157:3, 907-912
CrossRef159
Ian M. Thompson. (1997) Editorial: Prostate Cancer. The Journal of Urology 157:3, 919-920
CrossRef160
Joseph C. Presti, Regina Hovey, Vivek Bhargava, Peter R. Carroll, Katsuto Shinohara. (1997) Prospective Evaluation of Prostate Specific Antigen and Prostate Specific Antigen Density in the Detection of Carcinoma of the Prostate. The Journal of Urology907-911
CrossRef161
(1997) Prostate-Specific Antigen in Black Men. New England Journal of Medicine 336:2, 133-136
Full Text162
Judd W. Moul. (1997) Editorial: Radical Prostatectomy and Cryotherapy-Some Answers, More Questions. The Journal of Urology 157:1, 256-257
CrossRef163
Judd W. Moul. (1997) Editorial. The Journal of Urology256-257
CrossRef164
Ted O. Morgan, David G. McLeod, Eric S. Leifer, Gerald P. Murphy, Judd W. Moul. (1996) Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 48:6, 76-80
CrossRef165
Oesterling, Joseph E., . (1996) Age-Specific Reference Ranges for Serum PSA. New England Journal of Medicine 335:5, 345-346
Full Text166
Ted O. Morgan, David G. McLeod, Eric S. Leifer, Judd W. Moul, Gerald P. Murphy. (1996) Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. The Prostate 29:S7, 58-63
CrossRef
- Letters
